Evolent Health
EOLS Small CapHealthcare · Drug Manufacturers - Specialty & Generic
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Evolent Health en bref
Evolent Health (EOLS) is currently trading at 5,79 € with a market capitalization of 381 M €. The 52-week range spans from 3,37 € to 8,90 €; the current price is 35% below the yearly high. Year-over-year revenue growth stands at +6.7%.
💰 Dividende
Evolent Health currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
6 analystes évaluent Evolent Health (EOLS) au consensus : Achat Fort. L'objectif de cours moyen est de 12,80 €, soit un potentiel de +121.22% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 8,73 € à 17,45 €.
Evolent Health : la thèse d'investissement en détail
Evolent Health (EOLS) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
With a gross margin near 66.05%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 121.22% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
À surveiller
- The analyst consensus price target implies 121.22% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Marge brute élevée de 66.05% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Strong Buy
- –Actuellement non rentable
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility, elevated short interest (9.32%).
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Evolent Health?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
